Legend Biotech shares are trading lower. The company announced the presentation of first-in-human LB2102 results in solid tumors and new CARVYKTI data in multiple myeloma at ASCO 2026.

Benzinga Newsdesk www.benzinga.com Neutral 77.8%

Neg 0% Neu 77.8% Pos 0%

Comments

No comments yet. Be the first!